- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Abstract 652
VIROLOGICAL RESPONSE TO ENTECAVIR IS ASSOCIATED WITH LOW PROBABILITY OF DEVELOPING HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B PATIENTS WITH CIRRHOSIS
S.S. Kim*, S.J. Ahn, S.Y. Park, G.W. Song, J.Y. Cheong, S.W. Cho
Ajou University School of Medicine, Suwon, Republic of Korea. *[email protected]
Background and aims: The aim of this study was to assess the risk for the development of hepatocellular carcinoma (HCC) according to the underlying liver status and virological response (VR) to entecavir (ETV) in chronic hepatitis B patients with cirrhosis.
Patients and methods: A total of 324 patients with cirrhosis were treated with ETV for ≥ 6 months and were followed up (mean duration 36.0 months) for the occurrence of HCC. Patients who developed HCC within 6 months were excluded. VR was defined as HBV DNA undetectability (HBV DNA < 2000 copies/mL until June, 2008 and < 20 IU/mL after July, 2008).
Results: Two hundred and twenty (67.9%) patients had compensated cirrhosis and remaining (32.1%) patients had decompensated cirrhosis. The 5-year prevalence of HCC was 28.5%. Univariate analysis showed that increasing age (p = 0.002), male gender (p = 0.008), diabetes mellitus (p = 0.012), hepatic encephalopathy (p = 0.017) were significant risks for development of HCC. Low platelet and low serum albumin showed a trend to be risks for developing HCC (p = 0.089 and p = 0.090, respectively). VR was associated with lower HCC risk (p = 0.000). Cox regression analysis showed that age over 50 (p = 0.000, RR 2.906) and male gender (p = 0.005, RR 2.887) were independent risks for the development of HCC. Patients with VR had low probability for development of HCC (p = 0.000, RR 0.056).
Conclusions: Antiviral treatment with ETV does not completely eradicate the risk of developing HCC in patients with cirrhosis. However, VR to ETV is associated with a lower probability of developing HCC. Older age and male gender were significant independent risk factors for developing HCC in ETV-treated chronic hepatitis B patients with cirrhosis.
Assigned speakers:
Dr. Soon Sun Kim, Ajou University School of Medicine , Suwon , Republic of Korea
Assigned in sessions:
26.04.2013, 09:00-18:00, Poster Session, P02-03b, Category 03b: Liver tumors: Clinical (epidemiology, diagnosis), Poster Area
|
|